Smith & Nephew plc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Smith & Nephew plc trades at $27.21 (market cap $11.31B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.71 (market cap $3.14B). The key difference: Smith & Nephew plc is far larger — about 3.6× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Smith & Nephew plc for 120 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| SNN | SPHD | |
|---|---|---|
Market Cap | $11.31B | $3.14B |
Volume | 1,050,005 | 1,461,349 |
Sector | Health | — |
52-Week High | $37.17 | $53.55 |
52-Week Low | $26.42 | $46.96 |
Typical Hold Time | 120 Days | 125 Days |
Enterprise Value | $14.35B | — |
Dividend Yield | 2.95% | — |
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
SPHD trades at $48.19, down 0.58% with a bearish technical outlook showing 17 sell signals versus 4 buy signals. The ETF maintains its high-dividend focus with recent payouts of $0.20-$0.21, though financial ratios remain unavailable. Technical indicators show oversold conditions with RSI at 6.33-14.37 levels while moving averages signal continued downward pressure.
The ETF faces headwinds from underperformance concerns versus peers like SCHD, with media highlighting decade-long return disparities. While monthly dividends appeal to income investors, the lack of quality screening in stock selection poses yield trap risks. Current sentiment leans cautious as analysts question the fund's total return potential amid market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →